Iktos leverages AI and robotics to transform drug discovery, integrating generative AI with automated synthesis and testing to accelerate the development of new treatments.

Iktos

Aspen Neuroscience leverages stem cell biology and genomics for Parkinson's disease treatment. The self-described leading company aims to provide a personalized cell therapy to safely turn the clock back on Parkinson's disease.

Aspen Neuroscience

TK Analytics provides microscopy image analysis services since 2018.

TK Analytics

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Carl Hansen

Kevin Heyries

Véronique Lecault

AbCellera Biologics Inc.

Iktos leverages AI and robotics to transform drug discovery, integrating Generative AI with automated synthesis and testing to accelerate the development of new treatments to improve patient care.

Biotechnology Research

Makya™

iktos | 7,435 followers on LinkedIn. Artificial intelligence for new drug design | We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.

Our de novo design algorithm is based on deep generative models with reinforcement learning.

Chief Financial Officer in Life Sciences Industry

Stéphane MILOT

AI-driven drug discovery to improve human lives

Philip Laut

SVP, Head Drug Discovery

Alexis Denis

Investment Principal at Debiopharm Innovation Fund | Venture Capital | Digital Health, TechBio & AI

Vincent Lepreux

iktos

(🇬🇧 message below) LinkedIn コミュニティーの皆様こんにちは！ イクトスAPACチームです 🙂 11月20日から京都で開催される第41回メディシナルケミストリーシンポジウムに参加します。 ご参加予定の方は是非弊社の企業展示スペースにお立ち寄りください。第６会場東館２階セミナー室、ブース番号は３０です。 最終日の11月22日（金）にはランチョンセミナーにてCSOのQuentinが講演を行います。 イクトスのAI・自動化技術がどのように創薬研究を加速させるのか、弊社の事例を用いながらご紹介いたします。イクトスについてご存知の方もそうでない方も是非ご参加ください！ 当日会場で皆様にお会いできるのを心待ちにしています。 🌟 The Iktos team will be participating in the 41st Medicinal Chemistry Symposium in Kyoto 🇯🇵 November 20-22. Quentin Perron , Hideyoshi Fuji , Victoire M. L. Cachoux and Mizuki Ebihara look forward to meeting with you! If you plan to attend, please stop by our booth #30. They will be happy to discuss your drug discovery project together and highlight how our GenAI and Robotics platform can support it. 📢 Also, do not miss our CSO Quentin Perron’s lecture at the luncheon seminar. He will introduce how iktos ’ AI and automation technology accelerates drug discovery research using our company's case studies. ✨ Whether you already know about Iktos or not, please come and join us! 👉 https://lnkd.in/gmxPqJg5 #drugdiscovery #PharmaTech #InnovativeTherapies #artificialintelligence #Makya #Spaya #robotics

✨ Meet Dr. Dominique Bridon , a seasoned leader in pharmaceutical innovation ✨ We are excited to welcome him to our newly appointed Scientific Advisory Board! His extensive expertise in drug development will be instrumental in advancing Iktos’ pipeline of AI-first drug candidates. 🌟 🔬 With over 30 years of experience, Dr. Bridon has led drug development from early research through clinical studies across a wide range of therapeutic areas, including oncology, infectious diseases, metabolic, and cardiovascular disorders. His work has been instrumental in bringing innovative therapies to patients and advancing pharmaceutical science. 🚀 💼 Currently the CSO of Evexta Bio , a precision oncology start-up, Dr. Bridon has held senior management roles at Abbott , Ipsen , and EpiVax, Inc. , as well as in several biotechs acquired by larger players, including Optivia, Enobia Pharma , and Syntaxin. Additionally, he co-founded ConjuChem , which went public on the Toronto Stock Exchange and was later acquired. 🧬 💡 His deep understanding of the entire drug development lifecycle, combined with his strategic leadership and entrepreneurial acumen, will help Iktos mature and expand our pipeline, pushing the boundaries of AI-first drug discovery. We are honored to have him on board as we continue to drive innovation in drug discovery through GenAI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eW5pZe-7 #DrugDiscovery #PharmaTech #ArtificialIntelligence iktos

🚀 We’re thrilled to announce that our team will be attending the 9th #Investival Showcase as part of Jefferies Healthcare Week! Our CEO, Yann Gaston-Mathe , along with Marion Laguette , will be in London from November 18th to 21st. Don’t miss the opportunity to connect with them! 🤝 With over 60 small molecule projects spanning most therapeutic areas, iktos is at the forefront of de novo drug design, driven by our proprietary and powerful technologies. 💡 Our platform accelerates research projects from hit discovery to PCC in under 24 months—significantly faster than the traditional 3-5 years industry timeline. ⏱️ ✨ Join us to discover more about our vision for drug discovery and how we aim to revolutionize the field through GenAI, Robotics, and our growing development pipeline. 🌟 https://lnkd.in/eP7Cz4CS #Investment #biotech #PharmaTech #techbio #DrugDiscovery #ArtificialIntelligence

✨ Meet Dr. Thierry Masquelin , a visionary in drug discovery and robotics ✨ We are thrilled to welcome him to our newly appointed Scientific Advisory Board! His extensive expertise in robotics and automation will be instrumental in advancing iktos ’ AI-driven drug discovery platform. 🌟 🔬 With over 30 years of experience, Dr. Masquelin is renowned for creating the Lilly Life Science Studio ( #L2S2 )—a cutting-edge automated facility that transformed molecular design, synthesis, and biological testing. He also developed the world’s first Automated Synthesis and Purification Lab (ASPL), significantly streamlining drug discovery by integrating scientific functions and reducing cycle times. 🚀 🎓 Dr. Masquelin holds a PhD from the Université de Haute-Alsace - UHA and currently serves as COO of the ASPIRE initiative at the National Center for Advancing Translational Sciences (NCATS) . After senior roles at Eli Lilly and Company , he joined Recursion as Senior Director, where he developed a unified, multi-disciplinary platform to consolidate early drug discovery phases. 🧬 💼 His leadership in robotics and automation, paired with his experience in medicinal chemistry, will help position Iktos as a global leader in AI-first drug discovery. We’re excited to have Dr. Masquelin on board as we push the boundaries of innovation in drug discovery through AI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

AI platforms are uniquely positioned to address unmet patient needs by driving first-in-class therapies! This insightful analysis by Luka Jelcic and Andrii Savytskyi , provides a valuable overview of the novelty of targets pursued by AI-first companies. At iktos , our pipeline is dedicated to advancing therapies that tackle emerging, less-explored targets. With the power of #GenAI and #robotics , we’re identifying novel chemical matter and accelerating H2L processes to open up new therapeutic possibilities. With experience across over 60 targets, we’ve focused our internal pipeline on oncology, inflammation, and autoimmune diseases—fields in need of innovative solutions that offer safer, more tolerable therapies for patients with chronic conditions. 👉 We’re attending #BIOEurope this week; reach out if you’d like to connect! #AIDrugDiscovery #Innovation #NovelTargets #PatientNeeds #PharmaTech #Iktos

🤝 Proven AI partner across 60+ targets! With experience in most therapeutic areas and a current internal pipeline focused on oncology, inflammation, and autoimmune diseases, iktos is ready to partner with you. Let’s leverage our GenAI and robotics platform to accelerate your drug discovery! 🚀 Connect with us at Proventa International ’s Medicinal Chemistry Strategy Meeting. 🌟 Avirup Bose and Matthew Medcalf will be there to explore partnership opportunities and discover how we can accelerate your R&D together! 🔬✨ 👉 To learn more : https://lnkd.in/gx_uvacq #Iktos #drugdiscovery #artificialintelligence #PharmaPartnership #robotics #Makya #Spaya

🌟 iktos is excited to participate in the upcoming Automated Synthesis Forum🇬🇧 Franck Le Vaillant , our Deputy Lab Head, will showcase how we are developing an autonomous drug discovery platform with a strong focus on our AI-driven approach to accelerate the synthesis of bioactive molecules. You won’t want to miss his talk! He will be joined by Nicolas Martin, PhD , our Director of European Business Development. They are both eager to connect with you at the forum to discuss how GenAI & Robotics can enhance your drug discovery process. 🤖💡 Looking forward to seeing you there! 👋 👉 https://lnkd.in/enUktD2a #robotics #artificialintelligence #PharmaTech #drugdiscovery #PharmaPartnership #Makya #Spaya #ASF2024

✨ Meet Friedrich Rippmann , PhD a visionary leader in AI-driven drug discovery ✨ We are thrilled to welcome him to our newly appointed Scientific Advisory Board! His pioneering work in integrating AI into drug discovery will be instrumental in advancing Iktos’s platform and accelerating pharmaceutical partnerships. 🌟 🔬 He is a seasoned drug discovery professional and former Director of Computational Chemistry and Biologics at Merck Group . As an early and visionary adopter of AI in pharma, he led transformative efforts to integrate AI and machine learning into drug discovery, revolutionizing how computational chemistry is applied across the pharmaceutical industry. His work on discovering and optimizing lead compounds and predicting molecular properties has had a lasting impact. 🚀 🎯 His extensive expertise in structure-based drug design and protein-ligand interactions has been critical in optimizing therapeutic candidates, while his current role as Director at CombinAble.AI reflects his ongoing commitment to innovation. There, he is driving the vision to make antibody candidates developable and manufacturable through novel proprietary computational methods. 🧬💡 💼 As a member of iktos ’ Scientific Advisory Board, Friedrich Rippmann will bring his deep expertise in computational modeling and its integration into pharma, playing a pivotal role in enhancing our AI-first drug discovery partnerships. We are excited to have his guidance as we continue to transform drug discovery with AI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

📖 Don’t miss the latest editorial in the Journal of Medicinal Chemistry from American Chemical Society . Weijun Xu explores how the growing synergy between Computer-Aided Drug Design (CADD) and Artificial Intelligence in Drug Discovery (AIDD), are unlocking complex therapeutic challenges and paving the way for next-gen medicines 💊. 💻 The article gives an up-to-date look at computational innovations—from deep learning to advanced molecular docking—and highlights key players like Insilico Medicine , Exscientia , Recursion , iktos , and more. 🌟 A perfect Friday read on the trends shaping the future of pharma, where AI-driven innovation is just getting started! ⚡️ 🔗 Read more: https://lnkd.in/ehtA3VeD #CADD #AIDD #ArtificialIntelligence #DrugDiscovery #PharmaTrends ACS Publications #JournalOfMedicinalChemistry

✨ Meet Dr. Laurent Debussche , first-in-human drug discovery expert✨ We are excited to welcome him to our new Scientific Advisory Board! His expertise will be invaluable in accelerating our AI-driven drug discovery pipeline to address unmet patient needs. 🌟 🔬 With over 35 years of experience in oncology R&D, Dr. Debussche has held senior leadership roles at major pharmaceutical companies. Most recently, he served as VP Global Head of Oncology Research at Sanofi , where he advanced several first-in-human oncology drug candidates. His work spans a wide range of technologies, including small molecules, monoclonal antibodies (MAbs), nanobodies, antibody-drug conjugates (ADCs), cell engagers, and more. 🚀 🎓 Currently, Dr. Debussche serves as CEO of DLog Consulting, where he provides expert guidance in oncology drug development and strategic R&D leadership. He has co-authored over 60 international scientific publications and holds several dozen patents. 🏅 With a PhD in Molecular Biology from Pierre and Marie Curie University , he has led innovative research initiatives throughout his career, addressing unmet medical needs. 💡 His deep expertise in advancing first-in-human targets to clinical development will be key to accelerating iktos ’s AI-first drug discovery pipeline. We are delighted to have Dr. Debussche on board as we continue our mission to revolutionize drug discovery through AI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

Metric
Company Name	Iktos	Aspen Neuroscience	TK Analytics	AbCellera Biologics Inc.
Symbol				ABCL
MSH ID	COM:IKTOS	COM:ASPENNEUROSCIENCE	BIO:TKANALYTICS	COM:ABCELLERA
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Technology	Healthcare
Industry	Pharmaceuticals	Biotechnology	Scientific Software & Image Analysis	Biotechnology
Country	FR	US	SI	CA
Stage	Series A
Employee Count				586
Website	iktos.com	aspenneuroscience.com	tkanalytics.bio	abcellera.com
LinkedIn	iktos	aspen-neuroscience	tkanalytics
Founders

Metric
Market Cap		823.35M
Enterprise Value
Monthly Web Traffic	1.21K
Web Traffic Growth	-0.40
Valuation
Raised Capital	16.41M

Metric
Revenue				38.02M
Revenue (LTM)
Revenue (NTM)
Gross Profit				7.13M
EBITDA				-192.16M
Operating Income				-237.21M
Net Income				-146.40M
EPS				-0.51
Diluted EPS				-0.51
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.30
Operating Profit Margin				-6.15
EBITDA Margin				-5.05
Net Profit Margin				-3.85
Return on Equity				-0.12
Return on Assets				-0.10
Return on Capital Employed				-0.17

IKTO

COM:IKTOS

Iktos

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-11.06
P/B Ratio				1.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				35.65
EV Multiple				-4.01

Metric
Days Sales Outstanding				546.74
Days Payables Outstanding				4.09K
Days Inventory Outstanding				8.82
Operating Cycle				747.59
Cash Conversion Cycle				589.35
Asset Turnover				0.05

Metric
Operating Cash Flow				-43.88M
Free Cash Flow				-121.38M
Cash Flow to Debt				-0.56
Operating Cash Flow/Sales				-1.15
Free Cash Flow Yield				-0.05

Metric
Cash & Equivalents				133.32M
Accounts Receivable				-45.93M
Inventory				1.11M
Goodwill				47.81M
Debt to Capitalization				0.06
Debt to Assets				0.05
Current Ratio				8.34
Quick Ratio				10.96

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				1.21
R&D to Revenue				3.08
SG&A to Revenue				1.15